This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.
Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.
The Pan Mersey Area Prescribing Committee recommends the prescribing of DAPAGLIFLOZIN tablets (Forxiga®) for symptomatic chronic heart failure with reduced ejection fraction, following specialist recommendation in accordance with NICE TA679.
- GP letter: GP communication letter: Dapagliflozin in Heart Failure with Reduced Ejection Fraction (HFrEF)
- Treatment Pathway: Pathway for the use of Dapagliflozin in Heart Failure with Reduced Ejection Fraction (HFrEF)
- Patient information leaflet: SGLT 2 Inhibitors: Information for patients with heart failure
- Patient medical alert card: Dapagliflozin Heart Failure DKA Medical Alert Card